artesunate drug combination pyronaridine tetraphosphate

Also Known As:

pyronaridine tetraphosphate, artesunate drug combination; Artecom; Pyramax; pyronaridine and artesunate drug combination; pyronaridine tetraphosphate and artesunate drug combination; pyronaridine, artesunate drug combination; pyronaridine-artesunate; pyronaridine-artesunate drug combination

Networked: 42 relevant articles (11 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Duparc, Stephan: 12 articles (01/2022 - 04/2010)
2.	Borghini-Fuhrer, Isabelle: 11 articles (01/2022 - 04/2010)
3.	Ramharter, Michael: 7 articles (01/2022 - 09/2008)
4.	Fleckenstein, Lawrence: 7 articles (12/2015 - 09/2008)
5.	Ringwald, Pascal: 5 articles (01/2020 - 01/2016)
6.	Arbe-Barnes, Sarah: 4 articles (01/2022 - 02/2013)
7.	Shin, Jangsik: 4 articles (01/2022 - 02/2016)
8.	Khim, Nimol: 4 articles (01/2020 - 01/2016)
9.	Bélard, Sabine: 4 articles (02/2016 - 09/2008)
10.	Kurth, Florian: 4 articles (02/2016 - 09/2008)

Related Diseases

1.	Falciparum Malaria (Plasmodium falciparum Malaria) 01/01/2022 - "For the efficacy analysis, we included randomized controlled trials (RCTs) of pyronaridine-artesunate for treating uncomplicated P falciparum malaria. " 01/01/2019 - "Efficacy analysis: randomized controlled trials (RCTs) of pyronaridine-artesunate for treating uncomplicated P falciparum malaria.Safety" 09/15/2008 - "The aim of this study was to investigate a novel fixed-dose pyronaridine-artesunate combination for the treatment of uncomplicated falciparum malaria in Gabonese patients 2-14 years old. " 09/01/2002 - "The efficacy and safety of Artecom were assessed in an open randomized trial in adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand. " 05/13/2023 - "Pyronaridine-artesunate (PA) is a newer fixed-dose ACT recently prequalified by the WHO for the treatment of uncomplicated falciparum malaria. "
2.	Malaria 01/01/2022 - "In this study, we aimed to analyse the efficacy of pyronaridine-artesunate for the treatment of non-falciparum and mixed-species Plasmodium infections from a large phase 3b/4 clinical trial in central Africa. " 02/01/2016 - "Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial." 01/01/2021 - "Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study." 01/01/2020 - "This study supports the inclusion of pyronaridine-artesunate in national malaria treatment guidelines for Myanmar." 01/01/2022 - "Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial."
3.	Infections 06/17/2023 - "Therapeutic efficacy of pyronaridine-artesunate (Pyramax®) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia." 01/01/2022 - "This post-hoc analysis provides important evidence supporting the high efficacy of pyronaridine-artesunate against mono-infections with P malariae, P ovale curtisi, or P ovale wallikeri and mixed-Plasmodium infections in a real-world setting. " 01/18/2011 - "falciparum infection incidence until Day 42 were 2.5% with pyronaridine-artesunate, 6.1% with chloroquine (p = 0.048, log-rank test). " 01/18/2011 - "vivax mono-infection were randomized (1:1) to receive pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to 13.8:4.6 mg/kg) or chloroquine (standard dose) once daily for three days. " 01/01/2022 - "In individuals who were infectious before treatment, the median percentage reduction in mosquito infection rate 48 h after treatment was 100·0% (IQR 100·0 to 100·0) for individuals treated with pyronaridine-artesunate plus primaquine (n=18; p<0·0001) and dihydroartemisinin-piperaquine plus primaquine (n=15; p=0·0001), compared with -8·7% (-54·8 to 93·2) with pyronaridine-artesunate (n=17; p=0·88) and 50·4% (13·8 to 70·9) with dihydroartemisinin-piperaquine (n=16; p=0·13). "
4.	Vivax Malaria 01/01/2020 - "Four single-arm, prospective, clinical studies of pyronaridine-artesunate efficacy in uncomplicated Plasmodium falciparum or Plasmodium vivax malaria were conducted in Myanmar between 2017 and 2019. " 12/31/2022 - "Efficacy and safety of pyronaridine-artesunate (Pyramax®) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia." 01/01/2020 - "Efficacy and Safety of Pyronaridine-Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar." 10/01/2019 - "For Plasmodium vivax malaria, pyronaridine-artesunate day 28 ACPR was 98.3% (59/60) (95% CI, 91.1 to 100) and 100% (60/60) (95% CI, 94.0 to 100), respectively. " 02/21/2013 - "Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. "
5.	Acute malaria 02/21/2013 - "Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials."

Related Drugs and Biologics

1.	artemisinin (artemisinine)
2.	pyronaridine
3.	Lumefantrine Drug Combination Artemether (Coartem)
4.	Primaquine
5.	artenimol (dihydroartemisinin)
6.	piperaquine
7.	Artesunate
8.	artesunate drug combination pyronaridine tetraphosphate
9.	Antimalarials (Antimalarial Agents)
10.	Amodiaquine (Camoquin)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Retreatment
4.	Contraindications